Company Overview
Snapshot
Founded in December 2020 by Avner Spector, Curespec operates with 1–10 employees. The company has raised $7.4M across two funding rounds and holds a patent for its technology. In March 2026, a study on the feasibility and safety of its electrohydraulic acoustic therapy for hypertension in chronic kidney disease patients was published in Frontiers in Medical Technology.
Business overview
Curespec is a Health Tech & Life Sciences company specializing in medical devices that utilize noninvasive shockwave therapy. Its core product, Nephrospec, delivers electro-hydraulic acoustic therapy (eHAT) for the interrelated treatment of hypertension and chronic kidney disease (CKD). This technology aims to generate new blood vessels and restore function to damaged tissue, serving patients and healthcare providers in markets such as Europe, the United States, Southeast Asia, and Central America.
Strategic signal
The publication of a study in Frontiers in Medical Technology in March 2026, detailing the feasibility and safety of Curespec's electrohydraulic acoustic therapy for hypertension in chronic kidney disease patients, provides significant validation for the company's core technology. This signals to investors a strong scientific foundation and potential for clinical adoption, reinforcing Curespec's position in the medical device market for chronic disease management.
Log in to access full profile ›Company Intelligence Q&A
- What is Curespec's primary medical device product?
- Curespec's primary medical device product is Nephrospec, which uses electro-hydraulic acoustic therapy (eHAT) for the noninvasive treatment of hypertension and chronic kidney disease (CKD).
- When was Curespec founded?
- Curespec was founded in December 2020.
- What is the total capital raised by Curespec?
- Curespec has raised a total of $7.4 million across two funding rounds.
- Has Curespec obtained any regulatory approvals for its product?
- Yes, Curespec has obtained CE and AMAR approval in Europe and Israel, respectively, for its technology.
- What was a recent significant development for Curespec?
- In March 2026, a study on the feasibility and safety of electrohydraulic acoustic therapy for treating hypertension in patients with chronic kidney disease was published in Frontiers in Medical Technology.